Skip to main content
Article thumbnail
Location of Repository

Beyond Bevacizumab: an outlook to new antiangiogenics for the treatment of ovarian cancer

By Sven eMahner, Linn eWoelber, Volkmar eMueller, Isabell eWitzel, Katharina ePrieske, Donata eGrimm, Gunhild eKeller-v Amsberg and Fabian eTrillsch

Abstract

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib were developed to interfere with VEGF receptors and multiple additional intracellular pathways. Nintedanib and pazopanib significantly improved progression-free survival in two positive phase III trials for firstline therapy. A reliable effect on overall survival could, however, not be observed for any anti-angiogenic firstline therapies so far. In terms of recurrent disease, two positive phase III trials revealed that trebananib and cediranib are effective anti-angiogenic agents for this indication. Patient selection and biomarker guided prediction of response seems to be a central aspect for future studies. Combining anti-angiogenics with other targeted therapies to possibly spare chemotherapy in certain constellations, represents another very interesting future perspective for clinical trials. This short review gives an overview of current clinical trials for anti-angiogenic treatment strategies beyond bevacizumab. In this context, possible future perspectives combining anti-angiogenics with other targeted therapies and the need for specific biomarkers predicting response are elucidated

Topics: antiangiogenic therapy, ovarian cancer, Pazopanib, Nintedanib, Trebananib, Multikinase inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: Frontiers Media S.A.
Year: 2015
DOI identifier: 10.3389/fonc.2015.00211
OAI identifier: oai:doaj.org/article:49cb9b1bbafc40adaf0fc452ff37f827
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2234-943X (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/49cb9... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.